MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: GTCbio - Biopharmaceutical Conference
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Mike Pellini of Foundation Medicine to Present at 6th Oncology Biomarkers on March 20-22 in San Francisco - Michael Pellini, President and CEO of Foundation Medicine, Will Be Presenting at GTC’s 6th Oncology Biomarkers Conference, Taking Place in San Francisco, CA on March 20–22, 2013 - GTCbio.com
Mike Pellini of Foundation Medicine to Present at 6th Oncology Biomarkers on March 20-22 in San Francisco

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2012/12/19 - Michael Pellini, President and CEO of Foundation Medicine, Will Be Presenting at GTC’s 6th Oncology Biomarkers Conference, Taking Place in San Francisco, CA on March 20–22, 2013 - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Michael Pellini, President and CEO of Foundation Medicine, will give a presentation titled “Clinical Application of Comprehensive Cancer Genomic Analysis Utilizing Next Generation Sequencing (NGS) in Clinical Oncology” at GTC’s 6th Oncology Biomarkers Conference in San Francisco, CA on March 20–22, 2013.

Advances in our understanding of cancer biology and the explosion of discoveries emerging as academic and public efforts worldwide apply NGS to cancer genomes are being translated into real clinical benefits for cancer patients. The elucidation of genomic changes to inform rationally targeted therapies is becoming a reality and the pace of this translation from bedside to bench and back is accelerating. Foundation Medicine has developed a CLIA-certified pan-cancer diagnostic assay based on NGS technology to comprehensively interrogate all cancer-related genes using minimal DNA from FFPE tumor specimens to identify all classes of genomic alterations at high sensitivity and specificity.

Benefits of Dr. Pellini’s talk include:

1. Understand how comprehensive genomic sequencing is being applied in the clinic
2. Understand the benefits of comprehensive genomic sequencing vs. traditional hot-spot sequencing based on real clinical cases
3. Describe specific cases where targeted therapeutic options based on targeted therapies have resulted in improved patient outcomes

Dr. Pellini came to Foundation Medicine from Clarient, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Prior to his tenure with Clarient, Dr. Pellini served as Vice President of Life Sciences at Safeguard Scientifics, Inc. Prior to Safeguard, he was EVP and Chief Operating Officer at Lakewood Pathology Associates. Dr. Pellini received a B.A. from Boston College, an M.B.A. from Drexel University and an M.D. from Jefferson Medical College of Thomas Jefferson University.

The 6th Oncology Biomarkers conference is part of the Biomarker Summit 2013 and runs concurrently with two co-located tracks, which are:

2nd Neurological Biomarkers
2nd Inflammatory & Immunological Biomarkers

The summit will discuss a wide range of issues such as biomarker identification and validation strategies, patient stratification, enabling omics technologies, bioinformatics and systems biology techniques, regulatory and reimbursement trends and the development of companion diagnostics. These areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Mike Pellini of Foundation Medicine to Present at 6th Oncology Biomarkers on March 20-22 in San Francisco

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Limelon Advertising, Co.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)